Arrowhead Pharmaceuticals, Inc. (ARWR) earnings
ARWR earnings moved a median of -0.32% by the close. Quarterly and annual ARWR reports and results, each read against the price at its own news timestamp. Back to the ARWR overview →
31 measured ARWR earnings events.
Where these ARWR earnings landedvs 31 measured ARWR earnings reactions
| Middle 50% of ARWR earnings reactions | -2.98% to +2.57% |
|---|---|
| Median reaction (to close) | -0.32% |
| Measured reactions | 31 |
Point-in-time · zero look-ahead
Half of the 31 ARWR earnings events with a measured close landed between -2.98% and +2.57%; 45% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Arrowhead Pharmaceuticals Reports Fiscal 2026 Third Quarter Results | Press release | -1.20% | -0.66% | |
| Form 10-Q ARROWHEAD PHARMACEUTICAL For: Jun 30 | SEC filing · Form 10-Q | -1.20% | -0.66% | |
| Arrowhead Pharmaceuticals to Webcast Fiscal 2026 Third Quarter Results | Press release | +0.48% | +2.35% | |
| Arrowhead Pharmaceuticals Reports Fiscal 2026 Second Quarter Results | Press release | -4.65% | -4.98% | |
| Form 10-Q ARROWHEAD PHARMACEUTICAL For: Mar 31 | SEC filing · Form 10-Q | -4.65% | -4.98% | |
| Arrowhead Pharmaceuticals to Webcast Fiscal 2026 Second Quarter Results | Press release | +0.28% | -1.97% | |
| Arrowhead Pharmaceuticals Reports Fiscal 2026 First Quarter Results | Press release | +1.00% | -1.50% | |
| Form 10-Q ARROWHEAD PHARMACEUTICAL For: Dec 31 | SEC filing · Form 10-Q | +1.00% | -1.50% | |
| Arrowhead Pharmaceuticals to Webcast Fiscal 2026 First Quarter Results | Press release | -0.74% | +2.80% | |
| Form 10-K ARROWHEAD PHARMACEUTICAL For: Sep 30 | SEC filing · Form 10-K | +1.71% | +21.50% | |
| Form 10-K/A ARROWHEAD PHARMACEUTICAL For: Sep 30 | SEC filing · Form 10-K | +0.49% | +1.63% | |
| Arrowhead Pharmaceuticals Reports Fiscal 2025 Third Quarter Results | Press release | -1.61% | +5.59% | |
| Form 10-Q ARROWHEAD PHARMACEUTICAL For: Jun 30 | SEC filing · Form 10-Q | -1.61% | +5.59% | |
| Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Third Quarter Results | Press release | -1.64% | +2.12% | |
| Arrowhead Pharmaceuticals Reports Fiscal 2025 Second Quarter Results | Press release | -1.11% | -2.74% | |
| Form 10-Q ARROWHEAD PHARMACEUTICAL For: Mar 31 | SEC filing · Form 10-Q | -1.11% | -2.74% | |
| Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Second Quarter Results | Press release | -2.81% | +1.08% | |
| Arrowhead Pharmaceuticals Reports Fiscal 2025 First Quarter Results | Press release | +2.47% | +3.62% | |
| Form 10-Q ARROWHEAD PHARMACEUTICAL For: Dec 31 | SEC filing · Form 10-Q | +2.47% | +3.62% | |
| Arrowhead Pharmaceuticals to Webcast Fiscal 2025 First Quarter Results | Press release | -0.25% | +7.38% | |
| Form 10-K ARROWHEAD PHARMACEUTICAL For: Sep 30 | SEC filing · Form 10-K | -0.16% | +16.90% | |
| Arrowhead Pharmaceuticals Reports Fiscal 2024 Third Quarter Results | Press release | -1.20% | -6.36% | |
| Form 10-Q ARROWHEAD PHARMACEUTICAL For: Jun 30 | SEC filing · Form 10-Q | -1.20% | -6.36% | |
| Arrowhead Pharmaceuticals to Webcast Fiscal 2024 Third Quarter Results | Press release | +0.25% | +1.76% | |
| Arrowhead Pharmaceuticals Reports Fiscal 2024 Second Quarter Results | Press release | -1.88% | -13.34% | |
| Form 10-Q ARROWHEAD PHARMACEUTICAL For: Mar 31 | SEC filing · Form 10-Q | -1.88% | -13.34% | |
| Arrowhead Pharmaceuticals to Webcast Fiscal 2024 Second Quarter Results | Press release | +0.57% | -3.23% | |
| Arrowhead Pharmaceuticals Reports Fiscal 2024 First Quarter Results | Press release | -3.02% | -0.32% | |
| Form 10-Q ARROWHEAD PHARMACEUTICAL For: Dec 31 | SEC filing · Form 10-Q | -3.02% | -0.32% | |
| Arrowhead Pharmaceuticals to Webcast Fiscal 2024 First Quarter Results | Press release | +0.38% | +1.18% | |
| Form 10-K ARROWHEAD PHARMACEUTICAL For: Sep 30 | SEC filing · Form 10-K | -2.24% | -24.58% |
Keep exploring
More ARWR: analyst actions → · SEC filings → · ARWR overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Karyopharm Therapeutics Inc. (KPTI) | 392 | -0.45% | 45% |
| Rubius Therapeutics, Inc. (RUBY) | 392 | -0.32% | 45% |
| Axsome Therapeutics, Inc. (AXSM) | 391 | +0.05% | 52% |
| RA PHARMACEUTICALS (RARX) | 391 | -0.04% | 45% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.